Plus Therapeutics Inc
NASDAQ:PSTV
Plus Therapeutics Inc
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 14 full-time employees. The company went IPO on 2000-08-09. The firm is focused on developing treatments for patients battling cancer. The firm provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The firm is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The firm is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The firm also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 14 full-time employees. The company went IPO on 2000-08-09. The firm is focused on developing treatments for patients battling cancer. The firm provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The firm is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The firm is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The firm also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.
Financing & Runway: Plus Therapeutics raised $15 million in new equity and received $2 million in accelerated grants, securing funding through key milestones into mid-2026.
Pipeline Progress: Phase I ReSPECT-LM trial for REYOBIQ in leptomeningeal metastases (LM) established a recommended Phase II dose with promising efficacy and safety results. A multiple-dose trial is set to start soon.
Upcoming Milestones: The company plans to meet with the FDA in 2024 to define the registrational path for REYOBIQ and start a single-dose expansion trial targeting LM from breast cancer.
CNSide Diagnostics: CNSide, a proprietary CNS cancer testing platform, is on track for a commercial launch in 2025, initially via a focused rollout at major cancer centers.
Financials: 2024 net loss was $13 million on increased clinical spending; cash and investments were $3.6 million at year-end, with further grant revenue and private placement proceeds expected.
GBM & Pediatric Trials: The recurrent GBM trial is nearing full enrollment, with completion targeted in 2025. Pediatric brain cancer trial is advancing towards IND approval and is grant-funded.
Commercial Strategy: CNSide commercialization will be led by a focused in-house sales effort, not a large force, targeting key opinion leaders first and expanding as market access grows.
